Lv5
970 积分 2025-09-04 加入
Molecular Disease Monitoring in Patients With Relapsed/refractory B-Cell Lymphoma Receiving Anti-CD19 CAR T-Cell Therapy
2个月前
已完结
Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies
2个月前
已完结
Modifying CAR-T cells with anti-checkpoints in cancer immunotherapy: A focus on anti PD-1/PD-L1 antibodies
2个月前
已完结
Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML
3个月前
已完结
Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study
4个月前
已完结
Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML
4个月前
已完结
Does everyone with newly-diagnosed, untreated acute myeloid leukaemia need remission-induction chemotherapy before advancing to a transplant?
5个月前
已完结
The present and future for CAR-T cell therapy in adult B-cell ALL
6个月前
已完结
[Clinical efficacy of decitabine plus improved CAG chemotherapy and haplo-identical donor peripheral lymphocyte infusion regimen on elderly patients with high risk myelodysplastic syndrome and acute myeloid leukemia]
7个月前
已完结
[Clinical Efficacy of CAG Regimen Combined with Venetoclax, Chidamide, and Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia]
7个月前
已完结
皖公网安备34019202002308
